Impact of interleukin-6 in hematological malignancies by Burger, Renate
Review Article
Transfus Med Hemother 2013;40:336–343
DOI: 10.1159/000354194
Dr. Renate Burger
Division of Stem Cell Transplantation and Immunotherapy
2nd Department of Medicine, UKSH Campus Kiel
Schittenhelmstraße 12, 24105 Kiel, Germany
r.burger@med2.uni-kiel.de
© 2013 S. Karger GmbH, Freiburg
1660-3796/13/0405-0336$38.00/0
Accessible online at: 
www.karger.com/tmh
Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com
Received:  June 6, 2013
Accepted:  July 8, 2013
Published online: July 19, 2013
Impact of Interleukin-6 in Hematological Malignancies
Renate Burger
Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University Hospital Schleswig-Holstein and  
Christian-Albrechts-University of Kiel, Germany
Biology of Interleukin-6
Properties of IL-6 and Gene Regulation
Human IL-6 is a glycoprotein composed of 184 amino 
acids with a molecular weight of 21–28 kDa, depending on its 
degree of glycosylation. It has a 4-helix bundle structure 
made up of 4 long -helices arranged in an up-up-down-down 
topology. The gene for IL-6 is located at chromosome 7p21, 
and consists of 5 exons and 4 introns. The promoter region 
contains several transcription start sites with response ele-
ments for nuclear factor (NF)- B, CCAT/enhancer-binding 
protein beta (C/EPB formerly NF-IL6), and activator pro-
tein (AP)-1 [1, 2]. IL-6 is produced in many tissues and vari-
ous cell types including monocytes, macrophages, T and B 
lymphocytes, neutrophils, fibroblasts, epithelial and endothe-
lial cells, keratinocytes, mesangial cells, adipocytes, chondro-
cytes, osteoblasts, and more. Under normal physiological 
conditions, IL-6 gene expression is induced mostly by stimuli 
that cause an inflammatory response, such as TNF-  and - , 
IL-1, bacterial endotoxin and lipopolysaccharide, virus infec-
tion, and interferons [3, 4].
The IL-6 Receptor: Classical Signaling and Transsignaling
On target cells, IL-6 exerts its functions by first binding to 
its ligand-specific -receptor (IL-6R/CD126), a glycoprotein 
(gp) of 80 kDa, and then recruiting the signaling chain gp130 
(CD130) (fig. 1). The gp130 signal transducer is also used by 
other cytokines that comprise one family with partly redun-
dant activities [5]. The complete signaling competent receptor 
complex is a hexamer consisting of 2 molecules of IL-6, IL-
6R, and gp130 [6]. Upon gp130 dimerization, associated pro-
tein kinases, the so-called Janus kinases (JAK1, JAK2, and 
TYK2), become activated and phosphorylate specific tyrosine 
residues on gp130, which serve as docking sites for transcrip-
tion factors and adapter proteins. The main signaling path-
ways induced by gp130 are the activation of signal transducer 
and activator of transcription (STAT)-1 and STAT3, the Ras/
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Summary
Almost 3 decades have passed since the discovery and 
cloning of IL-6, and a tremendous amount of work has 
contributed to the current knowledge of the biological 
functions of this cytokine, its receptor, and the signaling 
pathways that are activated. The understanding of the 
role of IL-6 in human disease has led to the development 
of novel therapeutic strategies that block the biological 
functions of IL-6. In clinical studies, IL-6 and IL-6 receptor 
antibodies have proven efficacy in rheumatoid arthritis, 
systemic juvenile idiopathic arthritis, and Castleman’s 
disease, conditions that are known to be driven by IL-6. 
The focus of this overview is the role of IL-6 in the patho-
physiology of hematological malignancies.
Introduction
Almost 3 decades have passed since the discovery and 
cloning of IL-6, and a tremendous amount of work has con-
tributed to the current knowledge of the biological functions 
of this cytokine, its receptor, and the signaling pathways that 
are activated. The understanding about the role of IL-6 in 
human disease has led to the development of novel therapeu-
tic strategies that block the biological functions of IL-6. In 
clinical studies, IL-6 and IL-6 receptor antibodies have 
proven efficacy in rheumatoid arthritis, systemic juvenile idi-
opathic arthritis, and Castleman’s disease (CD), conditions 
that are known to be driven by IL-6. This review focusses on 
the role of IL-6 in the pathophysiology of hematological 
malignancies.
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Biological Functions of IL-6
Originally, IL-6 was identified as a T cell-derived factor 
which induces the terminal differentiation of activated B cells 
into antibody-producing plasma cells, and was therefore given 
the designation B cell stimulatory factor-2. Shortly after its 
cloning by the group of Kishimoto in 1986 [1], it became clear 
that a number of other factors which had been well character-
ized at that time were identical to IL-6 (table 1). Today, IL-6 
is known to be a cytokine with many multiple functions not 
limited to B cells but also involved in T cell immune re-
sponses, the regulation of hematopoiesis, induction of acute-
phase reactions and inflammation, as well as bone, cartilage 
and lipid metabolism [4, 5] (table 1).
Genetic studies in mice have contributed to the current un-
derstanding of the role of IL-6 in vivo. The phenotype of IL-6-
deficient mice is less severe than the pleiotropic functions 
would suggest. This can be explained by a certain degree of 
functional redundancy among the cytokines of the gp130 fam-
ily. IL-6 knockout mice are viable with normal embryogenesis 
and development, but they exhibit defects in antigen-specific 
antibody production and anti-viral response leading to in-
creased susceptibility to infections. They have defects in hemat-
opoiesis, acute-phase protein synthesis, chemokine induction 
and leukocyte recruitment, and hepatocyte regeneration [10, 
11]. In experimental disease models, IL-6 knockout mice show 
limited susceptibility to certain autoimmune and inflammatory 
conditions, CD, and plasmacytomas [8, 12]. Mice deficient in 
Raf/mitogen-activated protein kinase (MAPK) cascade, and 
the phosphatidylinositol-3 kinase (PI3K)/protein kinase B 
(AKT) pathway [6]. The resulting changes in gene expression 
patterns are dependent on the cell type, and involve proteins 
that regulate acute-phase and immune responses, prolifera-
tion, survival, cell cycle and differentiation, migration, angio-
genesis, neutrophil trafficking, bone metabolism, as well as 
cartilage and lipid metabolism [4].
In addition to the classical signaling through membrane-
bound IL-6R, a soluble form of the IL-6R (sIL-6R) is gener-
ated primarily through proteolytic cleavage (shedding). The 
sIL-6R can bind to free IL-6, and this complex acts as an ago-
nist and is capable of directly activating cells through mem-
brane-bound gp130, a process called transsignaling (fig. 1). A 
soluble gp130 increases the complexity of IL-6 signaling, it is 
generated by alternative mRNA splicing and acts as a natural 
antagonist [7]. While gp130 is ubiquitously expressed on al-
most all cells in the body, expression of the ligand-specific 
IL-6R is more restricted and mainly occurs on hepatocytes 
and certain leukocytes, in particular activated B cells, T cells, 
megakaryocytes, monocytes and neutrophils. Therefore, dur-
ing IL-6-mediated responses, the contribution of classic sign-
aling through the membrane IL-6R versus transsignaling in-
volving IL-6/sIL-6R depends on the physiological context and 
could have therapeutic implications [8, 9]. 
Fig. 1. The IL-6/IL-
6R/gp130 complex and 
main signaling pathways. 




of JAKs, and phosphor-
ylation of gp130. The 
signaling pathways lead 
to changes in gene tran-
scription (gp = glyco-
protein; JAK = Janus 
kinase; STAT = signal 
transducer and activa-
tor of transcription; 
SHP-2 = src homology 
2 domain-containing 
phosphatase; Grb2 = 
growth factor receptor-
bound protein; Sos = 
son-of-sevenless; 
MAPK = mitogen-acti-
vated protein kinase; 
MEK = MAPK kinase; 
PI3K = phosphatidyl-
inositol-3 kinase; mToR 
= mammalian target of 
rapamycin; p70S6K = 
p70 S6 kinase).
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tological tumors, acting in an autocrine or paracrine manner. 
Elevated serum levels of IL-6 are often correlated with adverse 
prognosis, and probably contribute to weight loss, night sweats, 
fever, and other paraneoplastic symptoms [3, 4]. 
In the hematopoietic system, a growth-regulatory role of 
IL-6 is predominantly found in tumors arising from the B cell 
compartment. IL-6 transgenic mice where the human IL-6 
gene was linked to the human Ig heavy chain enhancer, devel-
oped polyclonal hypergammaglobulinemia and diffuse plas-
macytosis with infiltration of the spleen and lymph nodes. By 
introduction of a Balb/c genetic background, monoclonal and 
transplantable plasmacytomas were induced [20]. IL-6-defi-
cient mice with Balb/c genetic background are completely re-
sistant to the development of plasmacytomas induced by pris-
tane oil demonstrating that IL-6 also plays a crucial patho-
genic role in the onset of plasma cell tumors in vivo. In a 
transgenic mouse model with human IL-6 driven by a major 
histocompatibility complex promoter, plasmacytoma inci-
dence and latency could be improved in the presence of c-myc 
[21]. In a different approach using retroviral-mediated trans-
fer of the IL-6 gene into hematopoietic cells, sustained IL-6 
production resulted in a syndrome in mice that resembled 
CD, a benign lymphoproliferative disease [22]. 
Castleman’s Disease
CD is a lymphoproliferative disease with benign hyperplas-
tic lymph nodes. In multicentric CD, a rare condition, polyclo-
nal plasmablasts accumulate in multiple lymph nodes with a 
propensity toward development of lymphoma. Constitutive 
production of IL-6 by B cells in the germinal centers of the af-
fected lymph nodes is associated with increased IL-6 serum 
levels [23]. High amounts of IL-6 may also be released by pe-
ripheral blood cells, providing an additional paracrine loop 
[24]. IL-6R polymorphism may also contribute to disease 
pathophysiology by being correlated to increased sIL-6R lev-
els in patients who carry at least 1 copy of the minor allele 
IL-6R display similar phenotypic characteristics to those of IL-
6-deficient mice with subtle differences, for example in wound 
healing. In contrast, targeted deletion of the gp130 gene results 
in embryonic lethality demonstrating the fundamental role of 
gp130 in development and hematopoiesis [13]. 
Viral IL-6
Viral IL-6 (vIL-6) is a variant of IL-6 encoded by Kaposi’s 
sarcoma-associated herpesvirus (KSHV) / human herpesvirus 
(HHV)-8 [14]. The gamma-herpesvirus is associated with Ka-
posi’s sarcoma and 2 B lymphoproliferative disorders, pleural 
effusion lymphoma and a subset of CD [15]. The protein has 
approximately 25% homology with human IL-6 and signals 
through gp130 to activate the JAK-STAT pathway similar to 
cellular IL-6 [16, 17]. The first evidence that vIL-6 is function-
ally active on human cells came from our own work using a 
newly established IL-6-dependent plasmacytoma cell line 
[18]. In these cells, vIL-6 stimulated proliferation which could 
be inhibited with IL-6R and gp130 antibodies. Others have 
shown that gp130 is sufficient for vIL-6 binding and signal 
transduction [19].
Role of IL-6 in the Pathophysiology of Hematological 
Tumors
IL-6 is an important factor in a variety of human disease 
states including cardiovascular disease, sepsis, fever, cachexia, 
insulin resistance, osteoporosis, and neurologic  disorders. Most 
notably, increased production of IL-6 contributes to the patho-
genesis of many chronic inflammatory and autoimmune dis-
eases [1]. There is growing evidence that there is also a link be-
tween chronic inflammation and tumor growth, shown for in-
flammatory bowel diseases and colitis-associated colon cancer. 
By virtue of its function as a cell growth modulator, IL-6 plays 
a role in many types of cancer comprising solid as well as hema-
Table 1. Cellular origin and biological activities of IL-6 [reviewed in 3, 4]
Synonyms Cells that produce IL-6 Biological activities
26-kDa protein monocytes/macrophages B cells: induction of immunoglobulin synthesis and differentiation
B cell differentiation factor (BCDF) Kupffer cells plasma cells: proliferation
B cell stimulatory factor-2 (BSF-2) fibroblasts hepatocytes: induction of acute phase proteins
Hepatocyte stimulating factor (HSF) epithelial cells T cells: growth and differentiation
Hybridoma growth factor (HGF) endothelial cells natural killer cells: augments activity
Interferon beta-2 (IFN-ß2) T and B cells megakaryocytes: maturation
Cytotoxic T cell differentiation factor (CDF) neutrophils neuronal cells: adrenocorticotropic hormone production
T cell-replacing factor (TRF) chondrocytes mesangial cells and keratinocytes: proliferation
Macrophage-granulocyte inducer type 2 (MGI-2) synoviocytes bone metabolism: activation of osteoclasts
Thrombopoietin adipocytes endothelial cells: chemokine production
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Pleural Effusion Lymphoma (PEL)
PEL or body cavity based lymphoma (BCBL) is an aggres-
sive immunoblastic B cell malignancy which usually presents 
as an effusion in the body cavities of patients with acquired 
immunodeficiency syndrome. It is almost always infected with 
KSHV and co-infected with Epstein-Barr virus (EBV) in up 
to 50% of cases. PEL cells constitutively produce IL-6 and ex-
press the IL-6R, and cell growth was inhibited by human IL-6 
antisense oligonucleotides [42]. In vivo growth of a PEL cell 
line in SCID mice could be delayed with a neutralizing anti-
IL-6-antibody which does not detect vIL-6 [43]. Both human 
and vIL-6 may contribute to PEL growth (see below).
Other Hematological Tumors
An implication of IL-6 in the pathophysiology of a variety 
of B-cell leukemias and lymphomas as well as some non-B cell 
malignancies has been suggested. In many cases, serum IL-6 or 
sIL-6R levels are elevated, as shown for low and high-grade 
non-Hodgkin’s lymphomas (NHL), Hodgkin’s disease (HD), 
and in adult T cell leukemia/lymphoma (reviewed in [3, 44]).
In B cell chronic lymphocytic leukemia (B-CLL), the most 
common leukemia, the leukemic cells can produce IL-6, and 
in a subset of patients, IL-6 serum levels are elevated and cor-
relate with disease stage and shorter survival rates. Serum 
sIL-6R levels also have prognostic value. In diffuse large B 
cell lymphoma (DLBCL), serum IL-6 levels correlate with 
prognosis and autocrine IL-6 production may provide prolif-
erative and anti-apoptotic signals. In an analysis of IL-6 ex-
pression in high-grade B cell lymphomas comprising Burkitt’s 
lymphomas (BL), DLBCL and immunoblastic lymphomas, 
IL-6 was mainly produced in tumor samples of non-BLs, but 
not in BLs. Immunohistochemical studies revealed that IL-6 
was expressed in the nonmalignant cells, while the tumor cells 
were positive for the IL-6R. Moreover, a correlation was 
found between IL-6 expression and the presence of immuno-
blasts within the malignant clone [45]. Others have found IL-6 
in the tumor cells of NHL samples [46]. An analysis of 2 EBV-
positive B cell lines from immunocompromized patients re-
vealed heterogeneity with regard to IL-6 requirement for cell 
growth; however, in cases that are responsive to IL-6, neutral-
izing antibodies were able to control tumor growth in SCID 
mice [47, 48]. In mantle cell lymphoma, another aggressive 
B cell NHL, IL-6 was identified as a key growth and survival 
factor acting in an autocrine fashion [49]. 
Serum IL-6 levels are also elevated in advanced HD and 
correlate with survival and B symptoms. HD-derived cell lines 
express both IL-6 and IL-6R. Moreover, IL-6 expression in 
Reed-Sternberg cells was detected in the majority of patients 
examined. IL-6 and IL-6R are expressed by blast cells in acute 
myeloblastic leukemia; however, both stimulatory as well as 
inhibitory effects on clonogenic blast growth have been de-
scribed, reflecting the heterogenous biology of this disease 
[50, 51]. Furthermore, IL-6 could have a differentiating func-
tion on acute promyelocytic leukemia cells [52].
[25]. The patients suffer from severe inflammatory symptoms, 
such as fever, weight loss, fatigue, anemia, increased levels of 
acute-phase proteins, and hypergammaglobulinemia. Treat-
ment with an antibody against the IL-6R resulted in allevia-
tion of the systemic manifestations [26], and high response 
rates were recently reported from a phase I study with the 
anti-IL-6 antibody siltuximab [27]. 
Multiple Myeloma
The role of IL-6 as a growth and survival factor in multiple 
myeloma (MM), a neoplasm of terminally differentiated B 
cells, is well established [28]. The disease is characterized by 
the accumulation of monoclonal plasma cells in the bone mar-
row (BM) that leads to serum monoclonal gammopathy, im-
mune suppression, and skeletal destruction [29]. In contrast to 
the differentiating activity on normal B cells, myeloma cells 
are stimulated to proliferate in response to IL-6 [30, 31]. Some 
myeloma cells can produce their own IL-6 [32], but BM stro-
mal cells are the main source, establishing a strong paracrine 
growth stimulation for the malignant plasma cells [33]. The 
production of IL-6 is upregulated by cytokines released into 
the surrounding tumor environment and by direct cellular 
contact between MM cells and stromal cells [34]. The orches-
tration of IL-6-induced signaling pathways contributes to the 
pleiotropic effects of IL-6 with regard to proliferation, sur-
vival, drug resistance, and migration of MM cells, thereby fa-
cilitating disease progression. Important survival signals are 
provided by activation of STAT3 which regulates the tran-
scription of proteins of the Bcl-2 family leading to protection 
from apoptotic cell death induced by various agents including 
corticosteroids [35, 36]. IL-6 also induces the Ras/Raf/MAPK 
and the PI3K/AKT pathway in MM cells [37]. In the presence 
of IL-6, cytokine-dependent human plasma cell lines could be 
obtained, but only from patients with terminal and extramed-
ullary disease [38, 39]. It is not entirely clear at which stage in 
the development of the disease or exactly which cell popula-
tions within the malignant clone are dependent on IL-6 or 
need additional signals. A recent study suggests that autono-
mous growth, as assessed by spontaneous colony formation, is 
regulated by insulin-like growth factor (IGF)-1 and stem cell 
factor (SCF) rather than IL-6 [40]. IL-6 is also a potent osteo-
clast-activating factor, and contributes to the development of 
bone lesions. Elevated levels of IL-6 and sIL-6 receptor are 
frequently present in the BM, plasma, and serum of MM pa-
tients, and are considered as an indicator of poor prognosis. 
Similar to CD, IL-6R polymorphism has been shown to be 
significantly correlated with increased sIL-6R levels [41]. MM 
accounts for approximately 10% of newly diagnosed hemato-
logical malignancies, affecting more than 20,000 people in the 
EU. It is still an incurable disease, and novel treatment strate-
gies are needed. Targeting IL-6 could be a promising ap-
proach, probably in combination with other treatments to 
overcome drug resistance. The anti-IL-6 antibody siltuximab 
is currently tested in multiple clinical studies (see also below).
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Therapeutic Implications
Preclinical and translational findings support a role for 
IL-6 in the pathophysiology of many diseases, and different 
strategies for blocking its activity have been developed. Con-
ventional agents like interferons or novel immunomodulatory 
drugs such as lenalidomide (Revlimid®, Celgene, Summit, NJ, 
USA) indirectly inhibit the effects of IL-6, for example by 
suppressing IL-6 expression. In contrast, specific inhibition of 
IL-6 can be achieved with monoclonal antibodies (mAb) 
against IL-6 or the IL-6R, with IL-6R antagonists and spe-
cially designed recombinant proteins (table 2). The increasing 
knowledge of the intracellular signaling pathways induced by 
IL-6 builds the molecular basis for targeted therapeutic ap-
proaches with small molecules [3, 8, 56].
Monoclonal Antibodies
Most of the clinical studies with mAb targeting IL-6 or 
IL-6R have been conducted in chronic inflammatory and au-
toimmune diseases where good responses can be achieved. 
There is yet no evidence showing which strategy is better, in-
hibiting the IL-6 ligand or blocking the IL-6R. At this time, 
only 1 antibody, tocilizumab (Actemra®/RoActemra® in the 
EU, Chugai, Tokyo, Japan/Roche, Basel, Switzerland), has 
been approved, but not for cancer treatment. Tocilizumab is a 
humanized anti-IL-6R antibody which binds to the IL-6 bind-
ing site of human IL-6R and competitively inhibits IL-6 sign-
aling [1]. The antibody binds to both membrane-bound and 
soluble IL-6R, and therefore is able to block classical IL-6 sig-
naling as well as transsignaling [57]. Tocilizumab was proven 
to be therapeutically effective in rheumatoid arthritis, sys-
temic juvenile idiopathic arthritis, and CD. It may be effec-
Role of Viral IL-6
HHV-8/KSHV infection is associated with 2 B-lymphopro-
liferative disorders, PEL or BCBL and multicentric CD [15]. 
In multicentric CD, HHV-8 infection is very common in 
HIV-positive patients. Here, a proportion of the plasmablas-
tic cells in the lymph nodes are infected with HHV-8 and ex-
press vIL-6 which is also present in high amounts in the circu-
lation [53]. Interestingly, vIL-6 can induce human IL-6 in pa-
tient-derived cells, but the biologic significance of the inter-
play between vIL-6 and cellular IL-6 remains unknown. Mice 
transgenic for vIL-6 spontaneously develop syndromes com-
parable to CD, inducing splenomegaly, multifocal lymphade-
nopathy, and plasmacytosis [54]. This phenotype was abro-
gated in mice with an IL-6-deficient genetic background, sug-
gesting that IL-6 may play an important role in the pathogen-
esis of HHV-8-associated multicentric CD. In PEL, the 
pleural and peritoneal effusions contain vIL-6 at high con-
centrations. IL-6 encoded by HHV-8 promotes autocrine 
growth of PEL cells, but seems to be expressed at only low 
levels in PEL cell lines. The regulation of vIL-6 expression is 
complex and dependent on virus reactivation. The relative 
contribution of vIL-6 versus cellular IL-6 in the pathophysiol-
ogy of PEL has remained open. 
A causative role for vIL-6 in the pathophysiology of MM 
had been suggested based on the initial finding of the presence 
of HHV-8 in BM dendritic cells of MM patients [55]. How-
ever, lack of serological evidence and contradictory results 
from polymerase chain reaction (PCR) studies have not clearly 
confirmed such an association. In summary, cellular and viral 
IL-6 often co-exist in HHV-8 associated diseases; therefore, 
their relationship in terms of regulation of expression and their 
specific contribution to disease remain to be defined.
Table 2. IL-6 inhibitors (reviewed in [8, 56, 66])
Agent Company Target/molecule Disease Clinical status
Tocilizumab (Actemra,  
RoActemra)
Chugai, Roche IL-6R/humanized mAb rheumatoid arthritis,  





REGN-88 (SAR153191) Regeneron/Sanofi- 
Aventis
IL-6R/human mAb rheumatoid arthritis clinical trials
Siltuximab (CNTO 328) Centocor IL-6/chimeric mAb multiple myeloma, B cell  
lymphoma, solid tumors
clinical trials
Sirukumab (CNTO 136) Centocor IL-6/human mAb rheumatoid arthritis clinical trials






FE999301 CONARIS/Ferring IL-6/sIL-6R complex / soluble 
gp130-Fc fusion protein
Crohn’s disease preclinical
Ruxolitinib (Jakafi/Jakavi,  
INCB018424/INC424)
Incyte/Novartis JAK1/JAK2 myelofibrosis;
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receptor binding, IL-6 is internalized and transports the toxin 
into the cell. In mouse models of MM, the immunotoxin has 
demonstrated antitumor effects [65].
Small Molecule Inhibitors of IL-6 Signaling Pathways
The signaling pathways induced by IL-6R/gp130 activation 
together contribute to the proliferative and anti-apoptotic ac-
tivities of IL-6. Targeting key components of these pathways, 
such as protein kinases, has become a novel strategy for thera-
peutic invention in cancer and other indications. Central me-
diators of IL-6 signaling are the tyrosine kinases of the JAK 
family by being directly associated with the gp130 membrane 
receptor. Inhibition of JAKs directly suppresses STAT activa-
tion, which in turn results in downregulation of important sur-
vival and angiogenic factors [66]. For example, JAK inhibition 
in an IL-6-dependent human plasma cell line resulted in 
growth inhibition in vitro and in vivo [67]. One advantage of 
signaling inhibition would be to overcome the redundancy 
that may occur among the gp130 family of cytokines [38]. De-
spite the adverse effects of JAK inhibitors due to the impor-
tant role of JAK1 and JAK2 in normal hematopoiesis, the 
first JAK inhibitor has been approved for treatment of pa-
tients with myelofibrosis, a myeloproliferative disorder carry-
ing an activating point mutation in the JAK2 gene [68]. Rux-
olitinib (Jakafi®/Jakavi®, formerly INCB018424/NVP-INC424, 
Incyte, Wilmington, DE, USA/Novartis Oncology, East 
Hanover, NJ, USA) is currently in several clinical studies for 
advanced hematological malignancies which may also harbor 
activation of the JAK/STAT pathway independent of cy-
tokine stimulation [69].
Conclusion
IL-6 is a pleiotropic cytokine, and its dysregulation is in-
volved in many diseases including chronic inflammatory and 
autoimmune disorders, coronary artery and neurologic dis-
ease, and in cancer. Innovative therapeutic strategies that 
block the biologic functions of IL-6 are being developed and 
are emerging in the clinic. The best responses with IL-6 and 
IL-6R antibodies were seen in rheumatoid arthritis, systemic 
juvenile idiopathic arthritis, and CD, conditions that are 
known to be driven by IL-6. There is clear evidence that over-
production of IL-6 is also involved in hematological malignan-
cies, particularly in B cell-derived and plasma cell tumors. The 
challenge is to identify patients that may benefit most from 
IL-6-blocking therapies, especially in heterogeneous diseases 
such as myeloma [70].
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tive in the treatment of HHV-8-associated diseases, and is 
currently in a phase II study in patients with symptomatic 
KSHV-associated multicentric CD (NCT01441063).
Several antibodies that neutralize IL-6 have been devel-
oped, but most of the clinical experience comes from studies 
with B-E8 (elsilimomab, Diaclone, Besançon, France) and 
CNTO 328 (siltuximab, Centocor Ortho Biotech Inc., Hor-
sham, PA, USA; formerly CLB IL6/8). B-E8 is a murine mAb 
that was used in early clinical trials in patients with MM and 
HIV-associated lymphoma, CNTO 328 is a chimeric human-
mouse antibody and therefore less immunogenic and with a 
prolonged half-life. Both antibodies were well tolerated and 
showed promising activity in MM, lymphoma, and B-lympho-
proliferative disorders [44]. One of the remarkable effects of 
antibody treatment was the alleviation of inflammatory symp-
toms such as fever and reduction of C-reactive protein which 
serves as a surrogate marker for IL-6 inhibition. Currently, 
there are multiple studies with siltuximab, completed or ongo-
ing, in patients with MM, B cell NHL, and CD. Results from a 
phase I study show high response rates in CD [27], and in 
combination with dexamethasone, clinical activity was seen 
even in dexamethasone-refractory MM [58].
A high-affinity, fully human derivative of B-E8, mAb 1339 
(licensed to GlaxoSmithKline, Brentford, Middlesex, UK), 
was developed which showed significant in vitro and in vivo 
activity in a preclinical SCID-hu model of myeloma with the 
IL-6-dependent cell line INA-6 [59]. 
Recombinant Proteins
Recombinant proteins have been designed that use very 
different mechanisms to block IL-6. None of these reagents 
have yet reached the clinical stage. A very promising ap-
proach was the development of IL-6R antagonists. These 
molecules are IL-6 variants generated by site-directed muta-
genesis. They bind to the membrane IL-6R with much higher 
affinity than natural IL-6 does, while the interaction with 
gp130 is abolished [60]. The superantagonist Sant-7 has shown 
promising activity on myeloma cells in vitro and in vivo, but 
has not been further developed for clinical use [18, 61, 62].
The development of a recombinant soluble gp130 (sgp130) 
protein was based on the finding that sgp130 is a natural in-
hibitor of IL-6/sIL-6R [63]. The protein is composed of sgp130 
linked to the Fc-region of human IgG. It mostly blocks IL-6 
transsignaling which primarily drives the inflammatory activi-
ties of IL-6. The molecule has shown effects in several in vivo 
models of arthritis, colitis, infection, allergy, and inflamma-
tion-induced cancer [64]. First clinical studies with FE999301 
(CONARIS Research Institute AG, Kiel, Germany/Ferring 
Pharmaceuticals, Saint-Prex, Switzerland) are planned for 
2013. It will need to be determined whether this inhibitor of-
fers a clinical advantage over mAb.
IL6(T23)-PE38KDEL is a fusion protein composed of IL-6 
and a truncated mutant form of Pseudomonas exotoxin. Upon 
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